Press Release

« Back
 Printer Friendly
TRACON Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting

SAN DIEGO, May 25, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, today announced presentations for its two most advanced clinical stage oncology product candidates, TRC105 and TRC102, at the upcoming American Society of Clinical Oncology (ASCO) annual meeting to be held June 2-6, 2017, in Chicago, Illinois.

The following is a summary of the four presentations that will be given at ASCO:

Poster Discussion Presentations
 
Title:  A Phase I Trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients 
  with solid tumors and lymphomas (Abstract #2518)
Presenter: Robert S. Meehan, MD, National Cancer Institute
Location: S Hall A, Poster Board 10 (poster display)
  Arie Crown Theater (poster discussion)
Date/Time: Monday, June 5, 2017, 8:00 AM – 11:30 AM, Central time (poster display)
  Monday, June 5, 2017, 11:30 AM – 12:45 PM, Central time (poster discussion)
   
Title:  NCCTG N1174: Phase I/comparative randomized Phase II trial of TRC105 plus 
  bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Abstract #2023)
Presenter: Evanthia Galanis, MD, Mayo Clinic
Location: S Hall A, Poster Board 265 (poster display)
  S404 (poster discussion)
Date/Time: Monday, June 5, 2017, 1:15 PM – 4:45 PM, Central time (poster display)
  Monday, June 5, 2017, 4:45 PM – 6:00 PM, Central time (poster discussion)
 
General Poster Presentations
 
Title:  Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF
  therapy (Abstract #11546)
Presenter: Yingmiao Liu, Ph.D., Duke University Medical Center
Location: S Hall A, Poster Board 246
Date/Time: Saturday, June 3, 2017, 1:15 PM – 4:45 PM, Central time
   
Title:  TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus 
  pazopanib alone in patients with advanced angiosarcoma (Abstract #TPS11081)
Presenter: Robin Lewis Jones, BSc, MB, MRCP, MD, Royal Marsden Hospital
Location: S Hall A, Poster Board 403a
Date/Time: Sunday, June 4, 2017, 8:00 AM – 11:30 AM, Central time

About Carotuximab (TRC105) 

TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in one Phase 3 and multiple Phase 2 clinical trials sponsored by TRACON or the National Cancer Institute for the treatment of solid tumors in combination with VEGF inhibitors. TRC105 has received orphan designation for the treatment of soft tissue sarcoma in both the U.S. and EU. The ophthalmic formulation of TRC105, DE-122, is currently in a Phase 1/2 trial for patients with wet AMD. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php.

About TRC102 

TRC102 (methoxyamine) is a novel, clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is currently being studied in multiple Phase 1 and Phase 2 clinical trials sponsored by the National Cancer Institute or Case Comprehensive Cancer Center. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php.

About TRACON 

TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.

Company Contact:
Casey Logan
Chief Business Officer
(858) 550‐0780 ext. 236
clogan@traconpharma.com

Investor Contact:
Andrew McDonald
LifeSci Advisors LLC
646-597-6987
Andrew@lifesciadvisors.com

Primary Logo

TRACON Pharmaceuticals, Inc.